Acute Myeloid Leukemia Treatment Market Outlook to 2023


Posted December 3, 2018 by harshita24

3rd December 2018: MarketResearchFuture announced addition of new report, titled “Acute Myeloid Leukemia Treatment Market Research Report - Global Forecast To 2023”.
 
Market Scenario
Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid buildup of abnormal white blood cells causes interference in the production of normal blood cells. AML has a propensity to increase towards age. Replacement of normal bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells etc. which causes symptoms such as fatigue, breathlessness, easy bruising and bleeding, and increased risk of infection. The market driving factors for acute myeloid leukemia (AML) are rise in risk factors such as exposures to carcinogens such as ionizing radiation, chemicals etc. Presence of other blood disorders and genetics is also involved for the higher risk of AML. Other market drivers are increasing number of cancer hospitals, greater awareness, good reimbursement scenario etc. The market constraints are poor cure rates of the present drugs, serious side effects of the drugs etc.
Considering all these factors the market for acute myeloid leukemia treatment is expected to reach $ 1.2 billion by the end of 2023, this market is projected to growing at a CAGR of Approx 5.3 % during 2017-2023.
GET SAMPLE REPORT @ https://www.marketresearchfuture.com/sample_request/3223
Key players of Global Acute Myeloid Leukemia Treatment Market
Key players profiled in the report are Johnson & Johnson, Pfizer Inc., Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi, Bristol Myers Squibb and others.
Segments
The global acute myeloid leukemia treatment market is segmented on the basis of disease type. Based on the disease type, the market has been segmented as myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia and megakaryocytic. Based on the treatment, the market has been segmented as chemotherapy, and hematopoietic stem cell transplantation. Chemotherapy is further sub-segmented into induction and post remission.
Intended Audience
Global acute myeloid leukemia treatment solutions providers.
Research and development (R&D) companies
Market research and consulting service providers
Academic institutes and universities

Table of Content: Key Points
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 MARKET DYNAMICS
4 MARKET FACTOR ANALYSIS
5 GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY DISEASE TYPE
6 GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY BY TREATMENT
7. GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY REGION
8. COMPETITIVE LANDSCAPE
…Continued
Access full report now: https://www.marketresearchfuture.com/reports/acute-myeloid-leukemia-treatment-market-3223
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By harshita
Country India
Categories Health , Medical , Science
Last Updated December 3, 2018